{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:34:25Z","timestamp":1777365265807,"version":"3.51.4"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"DOI":"10.2146\/ajhp110371","type":"journal-article","created":{"date-parts":[[2012,5,20]],"date-time":"2012-05-20T11:22:52Z","timestamp":1337512972000},"page":"933-943","source":"Crossref","is-referenced-by-count":36,"title":["Fidaxomicin: A novel macrocyclic antibiotic for the treatment of Clostridium difficile infection"],"prefix":"10.1093","volume":"69","author":[{"given":"Tonya","family":"Crawford","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, and Executive Director, Center for Advanced Design, Research, and Exploration, University of Illinois at Chicago, Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Huesgen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, and Executive Director, Center for Advanced Design, Research, and Exploration, University of Illinois at Chicago, Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Danziger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, and Executive Director, Center for Advanced Design, Research, and Exploration, University of Illinois at Chicago, Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041607001835500_b1-0690933","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1086\/659156","article-title":"Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals","volume":"32","author":"Miller","year":"2011","journal-title":"Infect Control Hosp Epidemiol."},{"key":"2019041607001835500_b2-0690933","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/CMR.00082-09","article-title":"The changing epidemiology of Clostridium difficile infections","volume":"23","author":"Freeman","year":"2010","journal-title":"Clin Microbiol Rev."},{"key":"2019041607001835500_b3-0690933","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa051639","article-title":"A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality","volume":"353","author":"Loo","year":"2005","journal-title":"N Engl J Med."},{"key":"2019041607001835500_b4-0690933","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"N Engl J Med."},{"key":"2019041607001835500_b5-0690933","first-page":"1201","article-title":"Severe Clostridium difficile-associated disease in populations previously at low risk\u2014four states, 2005","volume":"54","author":"Centers for Disease Control and Prevention (CDC)","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2019041607001835500_b6-0690933","article-title":"Clostridium difficile at a teaching hospital in Western Australia: providing insight into community acquisition","author":"Swingler"},{"key":"2019041607001835500_b7-0690933","article-title":"Clostridium difficile-associated diseases: a 2-year study","author":"Vicente"},{"key":"2019041607001835500_b8-0690933","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1001\/jama.294.23.2989","article-title":"Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease","volume":"294","author":"Dial","year":"2005","journal-title":"JAMA."},{"key":"2019041607001835500_b9-0690933","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1863-2378.2010.01352.x","article-title":"The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge","volume":"58","author":"Dubberke","year":"2011","journal-title":"Zoonoses Public Health."},{"key":"2019041607001835500_b10-0690933","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.18.2.247-263.2005","article-title":"Clostridium difficile toxins: mechanisms of action and role in disease","volume":"18","author":"Voth","year":"2005","journal-title":"Clin Microbiol Rev."},{"key":"2019041607001835500_b11-0690933","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/IAI.35.3.1032-1040.1982","article-title":"Purification and characterization of toxins A and B of Clostridium difficile","volume":"35","author":"Sullivan","year":"1982","journal-title":"Infect Immun."},{"key":"2019041607001835500_b12-0690933","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1016\/S0021-9258(17)34116-9","article-title":"Clostridium difficile toxin B acts on the GTP-binding protein rho","volume":"269","author":"Just","year":"1994","journal-title":"J Biol Chem."},{"key":"2019041607001835500_b13-0690933","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-1-60327-365-7_2","article-title":"Clostridium difficile and the disease it causes","volume":"646","author":"Nor\u00e8n","year":"2010","journal-title":"Methods Mol Biol."},{"key":"2019041607001835500_b14-0690933","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMra0707500","article-title":"Clostridium difficile\u2014more difficult than ever","volume":"359","author":"Kelly","year":"2008","journal-title":"N Engl J Med."},{"key":"2019041607001835500_b15-0690933","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1128\/MMBR.68.3.373-402.2004","article-title":"Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins","volume":"68","author":"Barth","year":"2004","journal-title":"Microbiol Mol Biol Rev."},{"key":"2019041607001835500_b16-0690933","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/501368","article-title":"Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters","volume":"193","author":"Geric","year":"2006","journal-title":"J Infect Dis."},{"issue":"(pt 2)","key":"2019041607001835500_b17-0690933","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1099\/jmm.0.45804-0","article-title":"Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains","volume":"54","author":"Barbut","year":"2005","journal-title":"J Med Microbiol."},{"key":"2019041607001835500_b18-0690933","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol."},{"key":"2019041607001835500_b19-0690933","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/QCO.0b013e32833229ce","article-title":"Clostridium difficile: controversies and approaches to management","volume":"22","author":"Bauer","year":"2009","journal-title":"Curr Opin Infect Dis."},{"issue":"(pt 2)","key":"2019041607001835500_b20-0690933","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1099\/jmm.0.45753-0","article-title":"Alternative treatments for Clostridium difficile disease: what really works?","volume":"54","author":"McFarland","year":"2005","journal-title":"J Med Microbiol."},{"key":"2019041607001835500_b21-0690933","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis."},{"key":"2019041607001835500_b22-0690933","unstructured":"Check Orphan. Optimer Pharmaceuticals receives orphan drug designation for fidaxomicin for the treatment of pediatric Clostridium difficile infection. www.checkorphan.org\/grid\/news\/treatment\/optimer-pharmaceuticals-receives-orphan-drug-designation-for-fidaxomicin-for-the-treatment-of-pediatric-clostridium-difficile-infection (accessed 2011 Jun 13)."},{"key":"2019041607001835500_b23-0690933","unstructured":"FDA News. FDA panel unanimously recommends approval of Optimer\u2019s fidaxomicin. www.fdanews.com\/newsletter\/article?issueId=14615&articleId=135661 (accessed 2011 Jun 13)."},{"key":"2019041607001835500_b24-0690933","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7164\/antibiotics.28.247","article-title":"Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies","volume":"28","author":"Parenti","year":"1975","journal-title":"J Antibiot."},{"key":"2019041607001835500_b25-0690933","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7164\/antibiotics.28.253","article-title":"Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization","volume":"28","author":"Coronelli","year":"1975","journal-title":"J Antibiot."},{"key":"2019041607001835500_b26-0690933","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7164\/antibiotics.40.567","article-title":"Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation, and antibacterial activity","volume":"40","author":"Theriault","year":"1987","journal-title":"J Antibiot."},{"key":"2019041607001835500_b27-0690933","doi-asserted-by":"crossref","first-page":"575","DOI":"10.7164\/antibiotics.40.575","article-title":"Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination","volume":"40","author":"Hochlowski","year":"1987","journal-title":"J Antibiot."},{"key":"2019041607001835500_b28-0690933","unstructured":"Optimer Pharmaceuticals. www.optimer-pharma.com\/gallery\/090207_Optimer-Poster_FINAL59827_93.pdf (accessed 2011 Jun 13)."},{"key":"2019041607001835500_b29-0690933","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/AAC.01045-07","article-title":"Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses","volume":"52","author":"Shue","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b30-0690933","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/JVI.33.3.945-953.1980","article-title":"Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis","volume":"33","author":"Osburne","year":"1980","journal-title":"J Virol."},{"key":"2019041607001835500_b31-0690933","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1128\/AAC.50.1.401-402.2006","article-title":"Mutation in the Bacillus subtilis RNA polymerase beta\u2019 subunit confers resistance to lipiarmycin","volume":"50","author":"Gualtieri","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b32-0690933","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1574-6976.1998.tb00364.x","article-title":"Eubacterial sigma-factors","volume":"22","author":"W\u00f6stem","year":"1998","journal-title":"FEMS Microbiol Rev."},{"key":"2019041607001835500_b33-0690933","article-title":"Resistance development, cross-resistance and synergy studies of OPT-80","author":"Babakhani"},{"key":"2019041607001835500_b34-0690933","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1128\/AAC.48.6.2280-2282.2004","article-title":"In vitro activity of OPT-80 against Clostridium difficile","volume":"48","author":"Ackermann","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b35-0690933","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/AAC.48.11.4430-4434.2004","article-title":"Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species","volume":"48","author":"Credito","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b36-0690933","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":"In vitro activities of OPT-80 and comparator drugs against intestinal bacteria","volume":"48","author":"Finegold","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b37-0690933","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.35.6.1108","article-title":"In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile","volume":"35","author":"Swanson","year":"1991","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b38-0690933","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.anaerobe.2009.09.005","article-title":"Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection","volume":"15","author":"Citron","year":"2009","journal-title":"Anaerobe."},{"key":"2019041607001835500_b39-0690933","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b40-0690933","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b41-0690933","article-title":"Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP-1118)","author":"Babakhani"},{"key":"2019041607001835500_b42-0690933","article-title":"Acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with fidaxomicin (FDX) versus vancomycin for Clostridium difficile infection","author":"Nerandzic"},{"key":"2019041607001835500_b43-0690933","article-title":"Fidaxomicin and vancomycin postantibiotic effect against C. difficile","author":"Babakhani"},{"key":"2019041607001835500_b44-0690933","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1128\/AAC.01842-09","article-title":"Effects of inoculum, pH, and cations on the in vivo activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile","volume":"54","author":"Babakhani","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b45-0690933","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.01442-07","article-title":"Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"2019041607001835500_b46-0690933","article-title":"Efficacy and safety of fidaxomicin (FDX) vs vancomycin (VAN) in Clostridium difficile infection (CDI) in 2 randomized controlled trials (RCT) with 1105 patients","author":"Crook"},{"key":"2019041607001835500_b47-0690933","article-title":"Randomized clinical trial (RCT) in Clostridium difficile (CDI) infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin (FDX) versus vancomycin (VCN)","author":"Crook"},{"key":"2019041607001835500_b48-0690933","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med."},{"key":"2019041607001835500_b49-0690933","unstructured":"Food and Drug Administration. Anti-Infective Drugs Advisory Committee meeting briefing document: Dificid (fidaxomicin tablets) for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficile-associated diarrhea (CDAD), and for reducing the risk of recurrence when used for treatment of initial CDI. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM249354.pdf (accessed 2011 Jun 8)."},{"key":"2019041607001835500_b50-0690933","volume-title":"Dificid (fidaxomicin) package insert","year":"2011"},{"key":"2019041607001835500_b51-0690933","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/430311","article-title":"Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole","volume":"40","author":"Musher","year":"2005","journal-title":"Clin Infect Dis."},{"key":"2019041607001835500_b52-0690933","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","article-title":"Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada","volume":"40","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis."},{"key":"2019041607001835500_b53-0690933","volume-title":"Red book: pharmacy\u2019s fundamental reference","author":"Murray","year":"2010","edition":"2010"},{"key":"2019041607001835500_b54-0690933","unstructured":"FirstWord. Optimer Pharmaceuticals to price Dificid at twice the cost of other C. diff treatments. www.firstwordplus.com\/Fws.do?articleid=7B3E908A05444A65868BAA422B925C33 (accessed 2011 Jun 15)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/11\/933\/28455262\/ajhp0933.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T23:19:58Z","timestamp":1642288798000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/11\/933\/5112568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,6,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110371","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,6,1]]},"published":{"date-parts":[[2012,6,1]]}}}